Elsevier

The Lancet

Volume 351, Issue 9106, 21 March 1998, Pages 851-852
The Lancet

Commentary
Adverse reactions to levodopa: drug toxicity or progression of disease?

https://doi.org/10.1016/S0140-6736(05)70285-3Get rights and content

References (8)

  • AM Bonnet et al.

    Does long term aggravation of Parkinson's disease result from non-dopaminergic lesions?

    Neurology

    (1987)
  • S Fahn

    Is Ievodopa toxic?

    Neurology

    (1996)
  • SG Diamond et al.

    Multi-center study of Parkinson's mortality with early versus late dopa treatment

    Ann Neurol

    (1987)
  • MD Yahr et al.

    Autopsy findings in parkinsonism following treatment with levodopa

    Neurology

    (1972)
There are more references available in the full text version of this article.

Cited by (40)

  • Ferroptosis and its potential role in the physiopathology of Parkinson's Disease

    2021, Progress in Neurobiology
    Citation Excerpt :

    Disparity in the potential neuroprotective actions of this drug may arise from L-DOPA’s interference with the striatal presynaptic dopamine transporter; standardly used as a reporter for nigro-striatal degeneration by DAT SPECT in clinical trials (Fahn et al., 2004; Fahn, 2005). The powerful symptomatic action and short half-life of L-DOPA also weakens its clinical use with motor complications such as “wearing off” and dyskinesia occurring 4-6 years after chronic use, depending on disease severity (Agid et al., 1998; Agid et al., 2002; Tran et al., 2018). To delay the onset of such complications, dopamine agonists, monoamine oxidase-B (MAO-B) inhibitors or catechol-O-methyltransferase (COMT) inhibitors are prescribed as concomitant therapies.

  • Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease

    2015, Neurobiology of Disease
    Citation Excerpt :

    The issue of l-DOPA toxicity has been raised in previous literature when discussing potential mechanisms of PD progression and development of dyskinesia and motor fluctuations, which are not observed in untreated patients. However, neither clinical (Agid et al., 1998; Jenner and Brin, 1998) nor experimental studies (Lindgren et al., 2007; Murer et al., 1998) have been able to prove that l-DOPA accelerate DA cell loss in PD, nor that is causes neurodegeneration in the Str. However, there is evidence of ongoing neuroinflammation in the brain of PD patients, and it remains to be established whether l-DOPA contributes to this process, at least in patients affected by l-DOPA-induced dyskinesia.

  • Intermittent l-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats

    2008, Brain Research
    Citation Excerpt :

    The antiparkinsonic l-DOPA therapy in Parkinson's disease (PD) still remains the best symptomatic treatment for motor deficits that are caused by the functional disturbance of the basal ganglia networks after the degeneration of dopaminergic neurons (Agid et al., 1998; Albin et al., 1989).

View all citing articles on Scopus
View full text